A novel Respiratory Syncytial Virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Lambert, Stacie L ^a   Aslam, Shahin ^b   Stillman, Elizabeth ^c   MacPhail, Mia ^d   Nelson, Christine ^e   Ro, Bodrey ^f   Sweetwood, Rosemary ^g   Lei, Yuk Man ^h   Woo, Jennifer C ⁱ   Tang, Roderick S ^j  

^a Department of Research ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Aragen Bioscience   (United States)

^d Modesto Junior College   (United States)

^e Stemcentrx   (United States)

^f GENENTECH INC   (United States)

^g SINGULEX INC   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ Torchbearer BioMedical LLC   (United States)

^j Meissa Vaccines Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOPYRANOSYL LIPID A; GLYCOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS F SUBUNIT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; COTTON RAT; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; EMULSION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LUNG LOBE; MOUSE; NONHUMAN; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SPRAGUE DAWLEY RAT; TH1 CELL; VACCINATION; VIRUS NEUTRALIZATION; ANIMAL; CELL MOTION; CHO CELL LINE; CRICETULUS; DISEASE MODEL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TH2 CELL; VIROLOGY;

MUS; RATTUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RODENTIA; SIGMODON;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; INTERFERON-GAMMA; LUNG; MICE; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; TH1 CELLS; TH2 CELLS; VACCINES, SUBUNIT;

EID: 84925625998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119509     Document Type: Article

References (59)

1. Walsh EE, Falsey AR. Respiratory Syncytial Virus Infection in Adult Populations. Infect Disord Drug Targets. 2012; 12(2):98-102. PMID: 22335500
2. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines. 2011; 10 (10):1415-33. doi: 10.1586/erv.11.120 PMID: 21988307
3. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991; 163(4):693-8. PMID: 2010624
4. Krilov LR. Palivizumab in the prevention of respiratory syncytial virus disease. Expert Opin Biol Ther. 2002; 2(7):763-9. PMID: 12387675
5. Graham BS, Davis TH, Tang YW, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory1 syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res. 1993; 34(2):167-72. PMID: 8233720
6. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 2004; 63(3):191-6. PMID: 15451187
7. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004; 189(2):233-8. PMID: 14722887
8. Maher CF, Hussell T, Blair E, Ring CJ, Openshaw PJ. Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 2004; 6(12):1049-55. PMID: 15380773
9. Olson MR, Varga SM. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines. 2008; 7(8):1239-55. doi: 10.1586/14760584.7.8.1239 PMID: 18844597
10. Cusi MG, Martorelli B, Di Genova G, Terrosi C, Campoccia G, Correale P. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. Immun Ageing. 2010; 7:14. doi: 10.1186/1742-4933-7-14 PMID: 20961416
11. Cherukuri A, Patton K, Gasser RA Jr., Zuo F, Woo J, Esser MT, et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clinical and vaccine immunology: CVI. 2013; 20(2):239-47. doi: 10.1128/CVI.00580-12 PMID: 23239796
12. Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med. 1997; 186(3):421-32. PMID: 9236194
13. Hussell T, Baldwin CJ, O'Garra A, Openshaw PJ. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol. 1997; 27(12):3341-9. PMID: 9464822
14. Munoz JL, McCarthy CA, Clark ME, Hall CB. Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol. 1991; 65(8):4494-7. PMID: 2072460
15. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines. 2008; 7(4):467-79. doi: 10.1586/14760584.7.4.467 PMID: 18444893
16. Hancock GE, Heers KM, Smith JD, Scheuer CA, Ibraghimov AR, Pryharski KS. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine. 2001; 19(32):4874-82. PMID: 11535341
17. Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock RE, et al. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine.
18. Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. J Gen Virol. 2014; 95:1043-54. doi: 10.1099/vir.0.062570-0 PMID: 24572813
19. Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N, et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine. 1997; 15(5):525-32. PMID: 9160520
20. Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, et al. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine. 2007; 25(29):5378-89. PMID: 17561317
21. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One. 2010; 5(10):e13677. doi: 10.1371/journal.pone.0013677 PMID: 21060869
22. Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun. 2011; 79(9):3492-500. doi: 10.1128/IAI.05257-11 PMID: 21690242
23. Huang K, Lawlor H, Tang R, MacGill RS, Ulbrandt ND, Wu H. Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing. Virus Genes. 2010; 40(2):212-21. doi: 10.1007/s11262-010-0449-8 PMID: 20111897
24. Cherukuri A, Stokes KL, Patton K, Kuo H, Sakamoto K, Lambert S, et al. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing. 2012; 9(1):21. doi: 10.1186/1742-4933-9-21 PMID: 23031690
25. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces. 2010; 75(1):123-32. doi: 10.1016/j.colsurfb.2009.08.022 PMID: 19748238
26. Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. J Virol. 2004; 78(20):11198-207. PMID: 15452239
27. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012; 31(2):109-14. doi: 10.1097/INF.0b013e31823386f1 PMID: 21926667
28. Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol. 2008; 84(3):748-59. doi: 10.1189/jlb.0907621 PMID: 18519743
29. Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol. 2005; 79(4):2050-7. PMID: 15681407
30. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008; 8(4):247-58. doi: 10.1038/nri2274 PMID: 18323851
31. Liu XM, Wang Z, Guo Y. Respiratory syncytial virus nephropathy in rats. Kidney Int. 2007; 71(5):388-96. PMID: 17200682
32. De Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today. 2011; 16(13-14):569-82.
33. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005; 560:11-8. PMID: 15932016
34. Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol. 2009; 21(4):185-93. doi: 10.1016/j.smim.2009.05.005 PMID: 19502082
35. Finkelman FD, Katona IM, Mosmann TR, Coffman RL. IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J Immunol. 1988; 140(4):1022-7. PMID: 3125247
36. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol. 2007; 96:179-204. PMID: 17981207
37. Ramanathan S, Gagnon J, Ilangumaran S. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. Arch Immunol Ther Exp (Warsz). 2008; 56(5):311-23. doi: 10.1007/s00005-008-0033-2 PMID: 18836862
38. Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. PLoS One. 2012; 7(12): e51618. doi: 10.1371/journal.pone.0051618 PMID: 23284726
39. Durand V, Mackenzie J, de Leon J, Mesa C, Quesniaux V, Montoya M, et al. Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles. Vaccine. 2009; 27(13):1912-22. doi: 10.1016/j.vaccine. 2009.01.109 PMID: 19368771
40. Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol. 2007; 178(2):748-56. PMID: 17202335
41. MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A. 2011; 108(19):7914-9. doi: 10.1073/pnas.1104588108 PMID: 21518876
42. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 2011; 6(1):e16333. doi: 10.1371/journal.pone.0016333 PMID: 21298114
43. Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, et al. Enhanced humoral and Type1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine. 2009; 27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081 PMID: 19679214
44. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985; 3(3):193-206. PMID: 3907188
45. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 1997; 230(2):155-66. PMID: 9143271
46. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A. 2012; 109(8):3089-94. doi: 10.1073/pnas.1115941109 PMID: 22323598
47. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85 (15):7788-96. doi: 10.1128/JVI.00555-11 PMID: 21613394
48. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011; 108(23):9619-24. doi: 10.1073/pnas. 1106536108 PMID: 21586636
49. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes. 2006; 33(2):235-52. PMID: 16972040
50. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. The American journal of pathology. 2011; 179(1):248-58. doi: 10.1016/j.ajpath.2011.03.003 PMID: 21703407
51. Newcomb DC, Boswell MG, Reiss S, Zhou W, Goleniewska K, Toki S, et al. IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation. Thorax. 2013; 68(8):717-23. doi: 10.1136/thoraxjnl-2012-202404 PMID: 23422214
52. Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis. 2012; 205(3):466-73. doi: 10.1093/infdis/jir769 PMID: 22147791
53. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 1996; 14(13):1214-8. PMID: 8961507
54. Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, et al. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or = 65 years of age. Vaccine. 2009; 27(42):5913-9. doi: 10.1016/j.vaccine.2009.07. 038 PMID: 19651171
55. Fries L, Glenn GM, Flyer D, Thomas DN, Jani D, Aideyan L, et al. RSV F Protein Vaccine is Well-Tolerated and Immunogenic in Elders. ICAAC 2013; Denver, CO2013.
56. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003; 9(9):1131-7. PMID: 12925846
57. Falsey AR, Walsh EE, Looney RJ, Kolassa JE, Formica MA, Criddle MC, et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virol. 1999; 59(2):221-6. PMID: 10459160
58. Lee S, Mittler RS, Moore ML. Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice. J Immunol. 2014; 192(1):293-9. doi: 10.4049/jimmunol. 1300453 PMID: 24285837
59. Mbawuike IN, Acuna C, Caballero D, Pham-Nguyen K, Gilbert B, Petribon P, et al. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol. 1996; 173(1):64-78. PMID: 8871602